Figure 5.

Triple combination therapy comprising of survivin knockdown, ABT-263 and trametinib is also effective against three-dimensionally (3D) cultured KRAS-mutant lung adenocarcinoma cells. (A) Schematic description of the experimental procedure and the representative image of a microspheroid in the 3D 'on-top' culture condition. (B) Representative images of microspheroids of 50 cells in 3D 'on-top' culture condition. The spheroids derived from NC siRNA- or BIRC5 siRNA (10 nM each)-transfected cells were cultured in the absence or presence of ABT-263 (1 μM) plus trametinib (25 nM) for 96 h. (C) Effects of the triple combination therapy on H358 and H441 spheroids. Viability was assessed as described in the schema in (A). Results are shown as the means ± SD; *P<0.05, ^**P<0.01.